Companies: 10,795·Total market cap: $144.5T
Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc.

ADILNASDAQHealthcare● Active
$2.20
$-0.01(-0.45%)
Market Cap$2111217
P/E Ratio
52W High$19
52W Low$1.31
SEC Filings

Adial Pharmaceuticals, Inc. (ADIL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001513525 · ADIL · NASDAQ · as of Jun 9, 2026

Filing snapshot

533
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001513525 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001213900-26-024175
Primary Document
ea0279150-10k_adial.htm
Source: data.sec.gov · CIK 0001513525 · Accession 0001213900-26-024175

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-08
8-KCurrent Report
CURRENT REPORT
2026-05-11Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
CURRENT REPORT
2026-05-11
View
10-QQuarterly Report
QUARTERLY REPORT
2026-05-08
View
8-KCurrent Report
CURRENT REPORT
2026-04-09
View
8-KCurrent Report
CURRENT REPORT
2026-03-06
View
10-KAnnual Report
ANNUAL REPORT
2026-03-05
View
8-KCurrent Report
CURRENT REPORT
2026-03-03
View
8-KCurrent Report
CURRENT REPORT
2026-02-24
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-18
View
8-KCurrent Report
CURRENT REPORT
2026-02-04
View
8-KCurrent Report
CURRENT REPORT
2026-01-06
View
DEF 14AProxy Statement
DEFINITIVE PROXY STATEMENT
2026-01-06
View
PRE 14APRE 14A
PRELIMINARY PROXY STATEMENT
2025-12-23
View
424B5424B5
PROSPECTUS SUPPLEMENT
2025-12-19
View
EFFECTEFFECT
EFFECT
2025-12-17
View
Showing 1–15 of 439 filingsForm 4 / 144 hidden· 533 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001513525  |  Exchange: NASDAQ · Healthcare

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) has submitted 533 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001513525, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Adial Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Adial Pharmaceuticals, Inc. 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical ADIL 10-K annual reports are available from 2011 through 2026.

Investors researching Adial Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ADIL SEC Filings · 8 questions

Adial Pharmaceuticals, Inc. (ADIL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 533 filings and access original documents at no cost. Adial Pharmaceuticals, Inc.'s CIK is 0001513525.

ADIL SEC filingsAdial Pharmaceuticals, Inc. SEC documentsfind ADIL 10-K